Clinical trial · Interventional
TACE Plus Bevacizumab for Hepatocellular Carcinoma With Portal Vein Invasion
Effects of Transcatheter Hepatic Arterial Chemoembolization (TACE) and Bevacizumab Arterial Perfusion on Tumor Load and Angiogenesis in Patients With Hepatocellular Carcinoma Invading Portal Vein
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective, randomized study designed to compare the efficacy of transcatheter hepatic artery chemoembolization (TACE) combined with bevacizumab arterial perfusion versus conventional therapy in patients with hepatocellular carcinoma (HCC) invading the portal vein. The study aims to evaluate the effects on tumor load, angiogenesis, and survival outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab Arterial Perfusion plus TACE | Drug | — | UNRESOLVED |
| Conventional Therapy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental: Observation Group (TACE + Bevacizumab)
- description
- Patients randomized to this arm received transcatheter hepatic artery chemoembolization (TACE) combined with arterial infusion of bevacizumab.
- interventionNames
- Drug: Bevacizumab Arterial Perfusion plus TACE
- type
- ACTIVE_COMPARATOR
- label
- Active Comparator: Control Group (Conventional Therapy)
- description
- Patients randomized to this arm received conventional therapy for HCC with portal vein invasion, serving as the active control.
- interventionNames
- Procedure: Conventional Therapy
Primary outcomes (3)
- measure
- Change in Tumor Load
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Aged between 18 and 70 years. * Confirmed diagnosis of Hepatocellular Carcinoma (HCC) with radiological evidence of portal vein invasion. * Preserved liver function (Child-Pugh class A or B). * Absence of severe cardiac, renal, or other vital organ dysfunctions. * Complete clinical and follow-up data available. * Provided written informed consent. Exclusion Criteria: * History of other malignancies within the past five years. * Prior or planned liver transplantation. * Severe comorbidities (e.g., decompensated cirrhosis, active bleeding, or cardiac disease). * Pregnant or lactating women. * Known hypersensitivity to bevacizumab or other components of the treatment.
References
Publications (0)
Data not yet available